TPP Pact: Bad For The World's Health

Doctors without Borders is none too thrilled about what’s transpiring behind closed doors at Trans-Pacific Partnership (TPP) free trade talks. The international medical humanitarian group fears IP provisions concerning pharmaceuticals will end up restricting access to affordable medicines for million of the world’s low- and middle-income residents.

In a recent letter to TPP negotiators, the organization contended that TPP “has the potential to become the most harmful trade pact ever” at least on the medicine access front.

The group depends on the availability of generic drugs to serve its constituents in the nearly 70 countries it serves. What it found in its efforts is that these more affordable medicines cut the cost of treatment by nearly 99 percent to less than $140 a patient per year.

The TPP pact, as it currently stands, according to leaked documents, contains “stringent” IP provisions championed by the United States that “go well beyond rules” already established by the World Trade Organization.

“These demands, summarized in an annex to this letter, will roll back public health safeguards and flexibilities enshrined in international law, and put in place far-reaching monopoly protections that will restrict generic competition and keep medicine prices unaffordable,” the letter reads.

Furthermore, Doctors without Borders expressed concern that the evolving TPP pact could be a global standard that future 21st century trade treaties will be patterned after.

Read the full letter at: